{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117682","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.926286+00:00","generated_at":"2026-06-21T20:44:13.482666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acurx reports Q3 net loss of $3.5M; cash $10.6M; Phase 2b enrollment continues","bullets":["Net loss of $3.5M ($0.32 per diluted share) for Q3 2022, vs $4.6M ($0.46) in Q3 2021.","Cash and cash equivalents $10.6M as of Sep 30, 2022, down from $13.0M at Dec 31, 2021.","Phase 2b trial for C. difficile infection enrollment ongoing; added sites, expecting up to 30 total.","Raised $4.225M in July 2022 via registered direct offering to institutional investor and executives.","R&D expenses $1.6M in Q3 2022 vs $1.1M in Q3 2021, increase due to Phase 2b costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117682","json":"https://secwatch.observer/filing/0001104659-22-117682.json","markdown":"https://secwatch.observer/filing/0001104659-22-117682.md","text":"https://secwatch.observer/filing/0001104659-22-117682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/tm2229909d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:44:13.482666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1aa2ab66469353a697315ed66bd17c47852b9e14","claim":"Acurx Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $3.5 million, EPS $0.32 per diluted share.","evidence_excerpt":"The Company reported a net loss of $3.5 million or $0.32 per diluted share for the three months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"net loss of $3.5 million"},{"label":"EPS","value":"$0.32 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b1831a8f0f004fb2f8670471f9fb0f2cdf0ad5a5","claim":"Acurx Pharmaceuticals, Inc. reported the nine months ended September 30, 2022 results: net income net loss of $8.8 million, EPS $0.84 per share.","evidence_excerpt":"a net loss of $8.8 million or $0.84 per share for the nine months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Net income","value":"net loss of $8.8 million"},{"label":"EPS","value":"$0.84 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}